The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...

The list recommending customs duty of 5% includes 74 drugs, while another suggesting full exemption has 69 drugs. A separate ...

June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and patient well-being.

AstraZeneca and Daiichi Sankyo have earned their second FDA approval for Datroway, scoring a nod for the drug to treat EGFR-mutated non-small cell lung cancer.